NCT06594094: An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)

Study type: INTERVENTIONAL. Phase: EARLY_PHASE1.

Publisher

ClinicalTrials.gov

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: ClinicalTrials.gov
Region: USA
Scope: Research
Published: August 3, 2026
Language: EN

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

Study type: INTERVENTIONAL. Phase: EARLY_PHASE1.

Source route

Continue on clinicaltrials.gov

Leave the platform to read the original full article on the publisher site.

Source: ClinicalTrials.gov

Scope: Research

Open original article

Related coverage

More related coverage

AHA Newsroom/3h ago

American Heart Association names Megan Starr executive director in the Central Valley

University of Minnesota/4h ago

NRRI unveils first-of-its-kind Direct Reduced Iron Simulator

UNC Chapel Hill/4h ago

Ackland’s $70M expansion to provide more space for art, learning

UNLP Health Sciences/4h ago

4ta CONVOCATORIA a IDEAS-PROYECTO DE CULTURA CIENTÍFICA

NCT06594094: An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE) | Pharma Surge